Who Owns Your Genes?

Scott E. Walker

The focus for the front cover of CJHP in 2002 will be the Human Genome Project and advances in science, medicine, and technology related to this project.

While it is widely hoped that the human genome project will assist us in treating genetic disease, the race to map the human genome also has a financial incentive. Although the Human Genome Project was completed with public (US) money, some large genome-mapping groups have done their work with private funding and have actually patented the DNA fragments that they have mapped. These DNA fragments, called expressed sequence tags (EST), may be thousands of bases in length and may carry real genetic information. EST strands may code for a specific function, so if a scientist finds a useful application in a particular coded sequence and that application depends on the DNA sequence, the application will in effect be patented.

Although private firms believe that patenting is necessary to protect their work, it may also restrict innovation, as independent scientists will have no incentive to work on patented sequences. However, the ethical issues related to this topic — even the thought that there could be private ownership of a part of the human body — are incredible. Many groups have pointed out that since genomic information cannot be invented, it should not be considered patentable. Furthermore, since the first person to observe the hypothalamus was not granted title to it or any of its hormones, why should a scientist be given title to a base-pair sequence from any chromosome, just because he or she was the first to sequence that strand?

An example of the effect of patenting a sequence or gene on health care relates to breast cancer. In 1994, the BRCA1 gene was identified as part of chromosome 17 and was sequenced. Subsequent studies have demonstrated that women with this mutation have a greater risk of breast cancer than those without it. As a result, a test was developed to detect the presence of the BRCA1 gene. However, Utah-based Myriad Genetics has a patent that covers the BRCA1 gene and is exercising the patent by insisting that any testing to detect the presence of the mutation must use its version of the test. The test kit sold by Myriad costs US$2400, whereas many laboratories can complete the test for one-third that amount. This situation has led a number of European countries to question the legitimacy of patenting the human genome.

References